Selected Publications
McPhail LD, Chung Y-L, Madhu B, Clark S, Griffiths JR, Kelland LR and Robinson SP. Tumour dose response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 2005; 11: 3705-3713. PubMed
Chung Y-L, Troy H, Judson IR, Leek R, Leach MO, Stubbs M, Harris AL and Griffiths JR. Non-invasive measurements of capecitabine metabolism in bladder tumors over-expressing thymidine phosphorylase by 19F MRS. Clinical Cancer Res 2004; 10: 3863-3870. PubMed
Chung Y-L, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P and Ronen SM. Magnetic Resonance Spectroscopic pharmacodynamic markers of Hsp90 inhibitor, 17-allylamino-17-demethoxygeldanamycin (17AAG) in human colon cancer models. JNCI 2003; 95: 1624-1633. PubMed
Griffiths JR, McSheehy PMJ, Robinson SP, Troy H, Chung Y-L, Leek RD, Williams KJ, Stratford IJ, Harris AL and Stubbs M. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 Wild-type tumors and tumors deficient in hypoxia-inducible factor-1 (HIF-1): Evidence of an anabolic role for the HIF-1 pathway. Cancer Res 2002; 62: 688-695. PubMed
Primary Research Publications
2008
Chung Y-L, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, Workman P, Leach MO, Beloueche-Babari M. Non-invasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia 2008; 10:303-13
Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung Y-L, Phillips R, Stubbs M, Griffiths JR, Airley R. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemotherapy and Pharmacology 2008; 61:377-393
Howe FA, McPhail LD, Griffiths JR, McIntyre DJ, Robinson SP. Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model. International Journal of Radiatation Oncology, Biology, Physics 2008; 71:1470-6
Kalber TL, Waterton JC, Griffiths JR, Ryan AJ, Robinson SP. Longitudinal in vivo susceptibility contrast MRI measurements of LS17T colorectal liver metastasis in nude mice. Journal of Magnetic Resonance Imaging 2008; 28:1451-8
Madhu B, Robinson SP, Howe FA, Griffiths JR. The effect of Gd-DTPA-BMA on choline signals of HT29 tumours detected by in vivo 1H MRS. Journal of Magnetic Resonance Imaging 2008; 28:1201-8
Mayr M, Liem D, Zhang J, Li X, Avliyakulov NK, Yang JI, Young G, Vondriska TM, Ladroue C, Madhu B, Griffiths JR, Gomes A, Xu Q, Ping P. Proteomic and metabolomic analysis of cardioprotection: Interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts. Journal of Molecular and Cellular Cardiology. 2008; Oct 26 [Epub ahead of print]
Mayr M, Yusuf S, Weir G, Chung YL, Mayr U, Yin X, Ladroue C, Madhu B, Roberts N, De Souza A, Fredericks S, Stubbs M, Griffiths JR, Jahangiri M, Xu Q, Camm AJ. Combined metabolomic and proteomic analysis of human atrial fibrillation. Journal of the American College of Cardiology 2008; 51:585-94
Mayr M, Zampetaki A, Sidibe A, Mayr U, Yin X, De Souza AI, Chung YL, Madhu B, Quax PH, Hu Y, Griffiths JR, Xu Q. Proteomic and metabolomic analysis of smooth muscle cells derived from the arterial media and adventitial progenitors of apolipoprotein E-deficient mice. Circulation Research 2008; 102:1046-56
Opstad KS, Bell BA, Griffiths JR, Howe FA. An investigation of human brain tumour lipids by high-resolution magic angle spinning 1H MRS and histological analysis. NMR Biomedicine 2008; 21:677-85
Opstad KS, Bell BA, Griffiths JR, Howe FA. Apparent T2 relaxation times of lipid and macromolecules: a study of high grade tumour spectra. Journal of Magnetic Resonance Imaging 2008; 27:178-84
Opstad KS, Bell BA, Griffiths JR, Howe FA. An assessment of the effects of sample ischaemia and spinning time on the metabolite profile of brain tumour specimens as determined by high-resolution angle spinning 1H NMR. NMR Biomedicine 2008; 21:1138-47
Opstad KS, Bell BA, Griffiths JR, Howe FA. Towards accurate quantification of metabolites, lipids and macromolecules in HRMAS spectra of human brain tumor biopsies using LCModel. Magnetic Resonance in Medicine 2008; 60:1237-42
Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung Y-L, Schulze A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metabolism 2008; 8:224-36
Wright AJ, Arús C, Wignen JP, Moreno-Torres A, Griffiths JR, Celda B, Howe FA. Automated quality control protocol for MR spectra of brain tumours. Magnetic Resonance in Medicine 2008; 59:1274-81
2007
Griffin JL, Nicholls AW, Daykin CA, Heald S, Kenn HC, Schuppe-Koistinen I, Griffiths JR, Cheng LL, Rocca-Serra P, Rubtsov DV, Robertson D. Standard reporting requirements for biological samples in metabolomics experiments: mammalian/in vivo experiments. Metabolomics 2007; 3(3):179-188
Griffiths J, Ewing G, Rogers M, Barclay SN, Martin A, McCabe J, Todd C. Supporting cancer patients with palliative care needs - District nurses' role perceptions. Cancer Nurs 2007; 30(2):156-162
Mcphail LD, Griffiths JR, Robinson SP. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-a4-phosphate by intrinsic susceptibility magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2007; 69(4):1238-1245
Opstad KS, Ladroue C, Bell BA, Griffiths JR, Howe FA. Linear discriminant analysis of brain tumour H-1 MR spectra: a comparison of classification using whole spectra versus metabolite quantification. NMR Biomed 2007; 20(8):763-770
Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Waterton JC. Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: A noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126. Int J Radiat Oncol Biol Phys 2007; 69(3):872-879
2006
Al-Saffar NMS, Troy H, de Molina AR, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res 2006; 66(1):427-434
Arias-Mendoza F, Payne GS, Zakian KL, Schwarz AJ, Stubbs M, Stoyanova R, Ballon D, Howe FA, Koutcher JA, Leach MO, Griffiths JR, Heerschap A, Glickson JD, Nelson SJ, Evelhoch JL, Charles HC, Brown TR, Cooperative Grp MRS. in vivo P-31 MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed 2006; 19(4):504-512
Charlton RA, Barrick TR, McIntyre DJ, Shen Y, O'Sullivan M, Howe FA, Clark CA, Morris RG, Markus HS. White matter damage on diffusion tensor imaging correlates with age-related cognitive decline. Neurology 2006; 66(2):217-222
Choke E, Cockerill GW, Dawson J, Chung YL, Griffiths J, Wilson RW, Loftus IM, Thompson MM. Hypoxia at the site of abdominal aortic aneurysm rupture is not associated with increased lactate. Ann N Y Acad Sci 2006; 1085:306-310
Cullis ER, Kalber TL, Ashton SE, Cartwright JE, Griffiths JR, Ryan AJ, Robinson SP. Tumor overexpression of inducible nitric oxide synthase (NOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. Microvasc Res 2006; 71(2):76-84
Julia-Sape M, Acosta D, Majos C, Moreno-Torres A, Wesseling P, Acebes JJ, Griffiths JR, Arus C. Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database. J Neurosurg 2006; 105(1):6-14
Madhu B, Waterton JC, Griffiths JR, Ryan AJ, Robinson SP. Response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo H-1 magnetic resonance spectroscopy. Neoplasia 2006; 8(7):560-567
McPhail LD, McIntyre DJO, Ludwig C, Kestell P, Griffiths JR, Kelland LR, Robinson SP. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 2006; 8(3):199-206
Nitkunan A, McIntyre DJO, Barrick TR, O'Sullivan M, Shen YJ, Clark CA, Howe FA, Markus HS. Correlations between MRS and DTI in cerebral small vessel disease. NMR Biomed 2006; 19(5):610-616
Payne GS, Troy H, Vaidya SJ, Griffiths JR, Leach MO, Chung YL. Evaluation of P-31 high-resolution magic angle spinning of intact tissue samples. NMR Biomed 2006; 19(5):593-598
Tate AR, Underwood J, Acosta DM, Julia-Sape M, Majos C, Moreno-Torres A, Howe FA, Graaf MV, Lefournier V, Murphy MM, Loosemore A, Ladroue C, Wesseling P, Bosson JL, Cabanas ME, Simonetti AW, Gajewicz W, Calvar J, Capdevila A, Wilkins PR, Bell BA, Remy C, Heerschap A, Watson D, Griffiths JR, Arus C. Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR Biomed 2006; 19(4):411-434
Weeks ME, Sinclair J, Butt A, Chung YL, Worthington JL, Wilkinson CRM, Griffiths J, Jones N, Waterfield MD, Timms JF. A parallel proteomic and metabolomic analysis of the hydrogen peroxide- and Sty1p-dependent stress response in Schizosaccharomyces pombe. Proteomics 2006; 6(9):2772-2796
2005
Howe FA, Connelly JP, Robinson SP, Springett R, Griffiths JR. The effects of tumour blood flow and oxygenation modifiers on subcutaneous tumours as determined by NIRS. Adv Exp Med Biol 2005; 566:75-81
Kalber TL, Smith CJ, Howe FA, Griffiths JR, Ryan AJ, Waterton JC, Robinson SP. A longitudinal study of R-2* and R-2 magnetic resonance imaging relaxation rate measurements in murine liver after a single administration of 3 different iron oxide-based contrast agents. Invest Radiol 2005; 40(12):784-791
Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005; 92(9):1599-1610
Mayr M, Chung YL, Mayr U, Yin XK, Ly L, Troy H, Fredericks S, Hu YH, Griffiths JR, Xu QB. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol 2005; 25(10):2135-2142
McPhail LD, Chung YL, Madhu B, Clark S, Griffiths JR, Kelland LR, Robinson SP. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 2005; 11(10):3705-3713
McSheehy PMJ, Port RE, Rodrigues LM, Robinson SP, Stubbs M, van der Borns K, Peters GJ, Judson IR, Leach MO, Griffiths JR. Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours. Cancer Chemother Pharmacol 2005; 55(2):117-128
Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IPM. Accumulation of Krebs cycle intermediates and over-expression of HIF1 alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005; 14(15):2231-2239
Porstmann T, Griffiths B, Chung Y-L, Delpuech O, Griffiths JR, Downward J, Schulze A. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005; 24(43):6465-6481
Robinson SP, Kalber TL, Howe FA, McIntyre DJO, Griffiths JR, Blakey DC, Whittaker L, Ryan AJ, Watertont JC. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 2005; 7(5):466-474
Troy H, Chung YL, Mayr M, Ly L, Williams K, Stratford I, Harris A, Griffiths J, Stubbs M. Metabolic profiling of hypoxia-inducible factor-1beta-deficient and wild type Hepa-1 cells: effects of hypoxia measured by 1H magnetic resonance spectroscopy. Metabolomics 2005; 1(4):293-303
2004
Arias-Mendoza F, Zakian K, Schwartz A, Howe FA, Koutcher JA, Leach MO, Griffiths JR, Heerschap A, Glickson JD, Nelson SJ, Evelhoch JL, Charles HC, Brown TR, Cooperative Grp MRS Applications C. Methodological standardization for a multi-institutional in vivo trial of localized P-31 MR spectroscopy in human cancer research. in vitro and normal volunteer studies. NMR Biomed 2004; 17(6):382-391
Chung Y-L, Troy H, Judson IR, Leek R, Leach MO, Stubbs M, Harris AL, Griffiths JR. Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy. Clin Cancer Res 2004; 10(11):3863-3870
Kostourou V, Troy H, Murray JF, Cullis ER, Whitley GS, Griffiths JR, Robinson SP. Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: An insight into the relationship of hypoxia and angiogenesis in vivo. Neoplasia 2004; 6(4):401-411
Mayr M, Chung YL, Mayr U, McGregor E, Troy H, Baier G, Leitges M, Dunn MJ, Griffiths JR, Xu QB. Loss of PKC-delta alters cardiac metabolism. Am J Physiol Heart Circ Physiol 2004; 287(2):H937-H945
Mayr M, Metzler B, Chung YL, McGregor E, Mayr U, Troy H, Hu YH, Leitges M, Pachinger O, Griffiths JR, Dunn MJ, Xu QB. Ischemic preconditioning exaggerates cardiac damage in PKC-delta null mice. Am J Physiol Heart Circ Physiol 2004; 287(2):H946-H956
Mayr M, Siow R, Chung YL, Mayr U, Griffiths JR, Xu QB. Proteomic and metabolomic analysis of vascular smooth muscle cells - Role of PKC delta. Circ Res 2004; 94(10):E87-E96
McIntyre DJO, Ludwig C, Pasan A, Griffiths JR. A method for interleaved acquisition of a vascular input function for dynamic contrast-enhanced MRI in experimental rat tumours. NMR Biomed 2004; 17(3):132-143
Noth U, Rodrigues LM, Robinson SP, Jork A, Zimmermann U, Newell B, Griffiths JR. in vivo determination of tumor oxygenation during growth and in response to carbogen breathing using 15C5-loaded alginate capsules as fluorine-19 magnetic resonance imaging oxygen sensors. Int J Radiat Oncol Biol Phys 2004; 60(3):909-919
Opstad KS, Murphy MM, Wilkins PR, Bell BA, Griffiths JR, Howe FA. Differentiation of metastases from high-grade gliomas using short echo time H-1 spectroscopy. J Magn Reson Imaging 2004; 20(2):187-192
Rodrigues LM, Howe FA, Griffiths JR, Robinson SP. Tumor R-2 * is a prognostic indicator of acute radiotherapeutic response in rodent tumors. J Magn Reson Imaging 2004; 19(4):482-488
Rodrigues LM, Stubbs M, Robinson SP, Newell B, Mansi J, Griffiths JR. The C-neu mammary carcinoma in Oncomice, characterization and monitoring response to treatment with herceptin by magnetic resonance methods. Magn Reson Mater Phys Biol Med 2004; 17(3-6):260-270
2003
Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 2003; 95(21):1624-1633
Howe FA, Barton SJ, Cudlip SA, Stubbs M, Saunders DE, Murphy M, Wilkins P, Opstad KS, Doyle VL, McLean MA, Bell BA, Griffiths JR. Metabolic profiles of human brain tumors using quantitative in vivo H-1 magnetic resonance spectroscopy. Magn Reson Med 2003; 49(2):223-232
Howe FA, Robinson SP, Rodrigues LM, Stubbs M, Griffiths JR. Issues in GRE & SE magnetic resonance imaging to probe tumor oxygenation. Adv Exp Med Biol 2003; 530:441-448
Kostourou V, Robinson SP, Whitley GSJ, Griffiths JR. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 2003; 63(16):4960-4966
McSheehy PMJ, Troy H, Kelland LR, Judson IR, Leach MO, Griffiths JR. Increased tumour extracellular pH induced by Bafilomycin A(1) inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. Eur J Cancer 2003; 39(4):532-540
Opstad KS, Provencher SW, Bell BA, Griffiths JR, Howe FA. Detection of elevated glutathione in meningiomas by quantitative in vivo H-1 MRS. Magn Reson Med 2003; 49(4):632-637
Robinson SP, McIntyre DJO, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, Waterton JC. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003; 88(10):1592-1597
Robinson SP, Rijken PFJW, Howe FA, McSheehy PMJ, van der Sanden BPJ, Heerschap A, Stubbs M, van der Kogel AJ, Griffiths JR. Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging 2003; 17(4):445-454
Rossiter HB, Ward SA, Howe FA, Wood DM, Kowalchuk JM, Griffiths JR, Whipp BJ. Effects of dichloroacetate on Vo(2) and intramuscular P-31 metabolite kinetics during high-intensity exercise in humans. J Appl Physiol 2003; 95(3):1105-1115
Tate AR, Majos C, Moreno A, Howe FA, Griffiths JR, Arus C. Automated classification of short echo time in in vivo H-1 brain tumor spectra: A multicenter study. Magn Reson Med 2003; 49(1):29-36
2002
Cudlip SA, Howe FA, Griffiths JR, Bell BA. Magnetic resonance neurography of peripheral nerve following experimental crush injury, and correlation with functional deficit. J Neurosurg 2002; 96(4):755-759
Griffiths JR, McSheehy PMJ, Robinson SP, Troy H, Chung Y-L, Leek RD, Williams KJ, Stratford IJ, Harris AL, Stubbs M. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1 beta (HIF-1 beta): evidence of an anabolic role for the HIF-1 pathway. Cancer Res 2002; 62(3):688-695
Murphy M, Loosemore A, Clifton AG, Howe FA, Tate AR, Cudlip SA, Wilkins PR, Griffiths JR, Bell BA. The contribution of proton magnetic resonance spectroscopy ((HMRS)-H-1) to clinical brain tumour diagnosis. Br J Neurosurg 2002; 16(4):329-334
Rodrigues LM, Robinson SP, McSheehy PMJ, Stubbs M, Griffiths JR. Enhanced uptake of ifosfamide into GH3 prolactinomas with hypercapnic hyperoxic gases monitored in vivo by P-31 MRS. Neoplasia 2002; 4(6):539-543
Rossiter HB, Ward SA, Howe FA, Kowalchuk JM, Griffiths JR, Whipp BJ. Dynamics of intramuscular P-31-MRS P-i peak splitting and the slow components of PCr and O-2 uptake during exercise. J Appl Physiol 2002; 93(6):2059-2069
Rossiter HB, Ward SA, Kowalchuk JM, Howe FA, Griffiths JR, Whipp BJ. Dynamic asymmetry of phosphocreatine concentration and O-2 uptake between the on- and off-transients of moderate- and high-intensity exercise in humans. J Physiol (Lond) 2002; 541(3):991-1002
Stubbs M, Robinson SP, Hui C, Price NM, Rodrigues LM, Howe FA, Griffiths JR. The importance of tumor metabolism in cancer prognosis and therapy, pre-clinical studies on rodent tumors with agents that improve tumor oxygenation. Adv Enzyme Regul 2002; 42:131-141
Other Publications
Chung Y-L, Griffiths JR. Using metabolomics to monitor anticancer drugs. Ernst Schering Foundation Symposium Proceedings. Springer-Verlag Berlin Heidelberg, 2008; 4:55-78
Griffiths JR. Diagnosing brain cancer without a biopsy - the eTUMOUR project. Public Service Review: European Union, 2008
Griffiths JR. A picture of health. Public Service Review: European Union, 2008; 16
Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PMJ, Price PM, Zweit J, Canc Res UK Pharmacodynamic Pharma. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 2006; 98(9):580-598
Mayr M, Mayr U, Chung YL, Yin XK, Griffiths JR, Xul OB. Vascular proteomics: Linking proteomic and metabolomic changes. Proteomics 2004; 4(12):3751-3761
Robinson SP, Griffiths JR. Current issues in the utility of F-19 nuclear magnetic resonance methodologies for the assessment of tumour hypoxia. Philos Trans R Soc Lond B Biol Sci 2004; 359(1446):987-996
Griffiths JR, Stubbs M. Opportunities for studying cancer by metabolomics: preliminary observations on tumors deficient in hypoxia-inducible factor 1. Adv Enzyme Regul 2003; 43:67-76
Stubbs M, Bashford CL, Griffiths JR. Understanding the tumor metabolic phenotype in the genomic era. Curr Mol Med 2003; 3(1):49-59
Griffiths JR, Tate AR, Howe FA, Stubbs M, Multi Inst Grp. Magnetic Resonance Spectroscopy of cancer - practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma. Eur J Cancer 2002; 38(16):2085-2093
